title: Effective control of skin reaction by air sandwich technique in a patient with IgE-κ myeloma treated with subcutaneous bortezomib injection.
abstract: A 53-year-old man initially presented with costalgia and was diagnosed with MM, based on the pathological findings. IgE monoclonal protein was detected by Serum protein electrophoresis (SPEP) and, surprisingly, IgE was elevated to 7,950,000 IU/ml. Monitoring the disease response during treatment, we employed quantification of serum M protein at SPEP, because IgE levels were found to be inaccurate and erratic. The patient was treated with CyBorD. He found injection site reactions to be very burdensome, due to extreme skin changes. The diameter of the hyperpigmentation area was 8 cm. To reduce the severity of this reaction, we used an air sandwich technique, and succeeded in ameliorating the skin changes.
authors.affiliation: Department of Hematology, Japanese Red Cross Medical Center.
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Honda
authors.forename: Junko
authors.initials: J
authors.lastname: Inoue
authors.forename: Shinto
authors.initials: S
authors.lastname: Shingaki
authors.forename: Kanzi
authors.initials: K
authors.lastname: Miyazaki
authors.forename: Yu
authors.initials: Y
authors.lastname: Abe
authors.forename: Eriko
authors.initials: E
authors.lastname: Sekine
authors.forename: Seiko
authors.initials: S
authors.lastname: Iki
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Tsukada
authors.forename: Kenshi
authors.initials: K
authors.lastname: Suzuki
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000069286:Bortezomib; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood* / Q000276:immunology; D007279:Injections, Subcutaneous / Q000379:methods; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012871:Skin Diseases / Q000276:immunology*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D007073:Immunoglobulin E; D000069286:Bortezomib